Lansoprazole 15 mg

DRUG5 trials

Sponsors

Daewoong Pharmaceutical Co. LTD., HK inno.N Corporation, Daejeon St. Mary's hospital, Addpharma Inc.

Conditions

Coronary Artery DiseaseGastro Esophageal RefluxHealed Erosive EsophagitisPeptic UlcerPreventive Peptic Ulcer

Phase 1

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

CompletedNCT06025773

Addpharma Inc.Gastro Esophageal Reflux

Start: 2023-09-15End: 2024-04-19Updated: 2024-08-01

Phase 3

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Daewoong Pharmaceutical Co. LTD.Healed Erosive Esophagitis

Start: 2020-07-02End: 2021-12-30Target: 406Updated: 2020-09-03

Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

CompletedNCT04784910

Daewoong Pharmaceutical Co. LTD.Peptic Ulcer

Start: 2021-05-21End: 2023-12-11Updated: 2024-07-08

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

HK inno.N CorporationPreventive Peptic Ulcer

Start: 2021-05-07End: 2024-07-31Target: 390Updated: 2023-07-14

Phase 4

The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

Daejeon St. Mary's hospitalCoronary Artery Disease

Start: 2023-05-01End: 2025-07-31Target: 300Updated: 2023-04-19

Related Papers

Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer

Gut and Liver2025-06-262 citations